Xiaflex collagenase clostridium histolyticum: Phase II data

Top-line data from an open-label, dose-escalation, U.S. Phase II trial in 14 lipoma patients showed that a single injection of Xiaflex met the primary endpoint of actively reducing the visible surface area of the lipoma as measured

Read the full 376 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE